Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model.
Reads0
Chats0
TLDR
It is suggested that dithiocarbamate exerts its effects via competitive chelation and removal of platinum coordinated to protein-bound sulfhydryl groups of the kidney tubule cells to inhibit nephrotoxic effects of cis-dichlorodiammineplatinum.Abstract:
The nephrotoxic effects of cis-dichlorodiammineplatinum(II) (NSC-119875) administered to male F344 rats at the median lethal dose (LD50; 7.5 mg/kg) were inhibited by treatment with sodium diethyldithiocarbamate (500 or 750 mg/kg) between 1 and 4 hr after cis-platinum administration. Those animals receiving cis-platinum alone had mean serum blood urea nitrogen levels of 234 mg/dl at the time of maximal toxicity (day 5); kidney sections revealed large areas of degeneration and necrosis. When dithiocarbamate rescue was carried out after cis-platinum treatment, mean blood urea nitrogen levels were in the range 56-95 mg/dl; kidney sections were grossly normal with a barely discernible band of degeneration at the corticomedullary junction. Gastrointestinal toxicity was observed in greater than 95% of the cis-platinum-treated rats but was totally absent in those receiving subsequent rescue treatment. A significant decrease in weight loss was also observed in the dithiocarbamate-rescued rats. Based on the chemistry of platinum-sulfur interactions and the observed time-dependence of the rescue treatment, it is suggested that dithiocarbamate exerts its effects via competitive chelation and removal of platinum coordinated to protein-bound sulfhydryl groups of the kidney tubule cells.read more
Citations
More filters
Journal ArticleDOI
Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
Journal ArticleDOI
Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery.
TL;DR: The synthesis of novel acid-responsive therapeutic nanoparticles (NPs) with sub-100 nm size consisting of polymer--cisplatin conjugates hold the promise to suppress cancer cell chemoresistance by rapidly releasing a high dose of chemotherapy drugs inside the tumor cells, thereby improving the therapeutic efficacy of the drug payload.
Journal ArticleDOI
Cisplatin Binding Sites on Human Albumin
Andrei I. Ivanov,John Christodoulou,John Parkinson,Kevin J. Barnham,Alan Tucker,John Rodney Woodrow,Peter J. Sadler +6 more
TL;DR: During the later stages of reactions of cisplatin with albumin, release of NH3 occurs due to the strong trans influence of Met sulfur, which weakens the Pt-NH3 bonds, and protein cross-linking is observed.
Journal Article
Pharmacokinetics and Dosage Reduction of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum in Patients with Impaired Renal Function
Merrill J. Egorin,D A Van Echo,S. J. Tipping,E A Olman,Margaret Y. Whitacre,B W Thompson,Joseph Aisner +6 more
TL;DR: Calculations for theoretical patients (both pretreated and nonpretreated) with CCr of 100 ml/min produce dosages very close to maximum tolerated dosages derived in actual Phase I trials, although the actual clinical utility of these predictive equations must await validation in prospective studies with larger numbers of patients.
Journal ArticleDOI
Nephrotoxicity Induced by Cancer Chemotherapy With Special Emphasis on Cisplatin Toxicity
Fernand Ries,Jean Klastersky +1 more
TL;DR: Cisplatin nephrotoxicity is clearly dose-related and used to be considered dose limiting; hyperhydration with mannitol-induced saline diuresis may allow administration of high doses and thus circumvent the dose-limiting effect of cisplatin-induced renal toxicity.
References
More filters
Journal ArticleDOI
High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.
Daniel M. Hayes,Esteban Cvitkovic,Robert B. Golbey,Ellen Scheiner,Lawrence Helson,Irwin H. Krakoff +5 more
TL;DR: A clinical trial was undertaken to improve the therapeutic index of cis‐plati‐num diammine dichloride with a concomitantly administered mannitol induced diuresis and CPDD administration, with Clinically significant responses in epidermoid carcinoma of the head and neck, adenocarcinomas of the ovary, and germ cell tumors of the testis.
Journal Article
Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).
TL;DR: Renal impairment was the dose-limiting toxicity in the single-dose escalation scheme used, and progressive renal failure contributed to the death of one patient, this Phase I investigation characterizes the toxicity and pharmacological disposition of the drug in 10 patients.
Journal ArticleDOI
The renal pathology in clinical trials of cis-platinum (II) diamminedichloride
TL;DR: It is suggested that mannitol‐induced diuresis has considerably decreased the renal toxic damage of CPDD therapy in these patients.
Journal ArticleDOI
Long term effect of Cis‐Diamminedichloride platinum (CDDP) on renal function and structure in man
TL;DR: CDDP resulted in a permanent, nonspecific renal injury in patients with testicular carcinoma, and future courses of CDDP may lead to clinically important chronic renal failure.
Journal ArticleDOI
Improvement of Cis‐dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model
TL;DR: The data presented indicate that a better therapeutic index has been achieved by osmotic diuresis with mannitol, and that the pharmocokinetics of the drug are unaltered.
Related Papers (5)
Effect of Diethyldithiocarbamate on cis-Diamminedichloroplatinum(II)-induced Cytotoxicity, DNA Cross-Linking, and γ-Glutamyl Transpeptidase Inhibition
Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.
S B Howell,R Taetle +1 more